-
1 Comment
4SC AG is currently in a long term downtrend where the price is trading 11.9% below its 200 day moving average.
From a valuation standpoint, the stock is 97.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 35.3.
4SC AG's total revenue sank by 37.3% to $52K since the same quarter in the previous year.
Its net income has increased by 0.3% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 7.7% to $-3M since the same quarter in the previous year.
Based on the above factors, 4SC AG gets an overall score of 2/5.
| ISIN | DE000A3E5C40 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | F |
| CurrencyCode | EUR |
| Dividend Yield | None |
|---|---|
| Beta | 2.0 |
| PE Ratio | None |
| Target Price | 5.5 |
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany. Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage. The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for VSC.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
